相关实验视频

Updated: Jul 11, 2025

Specificity Analysis of Protein Lysine Methyltransferases Using SPOT Peptide Arrays

Specificity Analysis of Protein Lysine Methyltransferases Using SPOT Peptide Arrays

Published on: November 29, 2014

氨酸乳酸化 (Kla) 可能是乳腺癌的新治疗点

Jian Deng¹, Xinyi Liao²

¹Department of Thyroid Breast Surgery, The Second Affiliated Hospital, Hengyang Medical School, University of South China, No. 35 Jiefang Avenue. Hengyang, Hengyang, 421001, China. drdengjian@163.com.

BMC medical genomics

|November 11, 2023

概括

激素 lysine 乳糖化 (Kla) 是一种新的乳腺癌 (BC) 预后生物标志物. 克拉影响瘤微环境,耐药性和免疫疗法,表明其作为治疗点的潜力.

科学领域:

生物化学生物化学
在瘤学瘤学.
基因组学就是基因组学.

背景情况:

基因组 lysine 乳糖化 (Kla) 是一种新兴的表观遗传修饰.
克拉已与各种癌症的进展有关.
克拉在乳腺癌 (BC) 的预后意义尚未完全阐明.

研究的目的:

为了研究Kla在乳腺癌的预后价值.
确定Kla特异性基因及其与BC的关联.
探索Kla对瘤微环境,治疗反应和患者结果的影响.

主要方法:

对BC的RNA表达数据是从癌症基因组图谱 (TCGA) 中分析的.
鉴定了差异表达的Kla特异基因 (DEKlaGs).
使用考克斯回归来构建预后模型,并结合了关键的Kla特异基因.
进行基因组丰富分析 (GSEA) 来预测受影响的途径.

主要成果:

分析了1073个BC样本和112个正常对照的队列.
在BC.发现了257个DEKlaG.
一个基于CCR7,IGFBP6,NDUFAF6,OVOL1和SDC1的预后模型证明了BC风险.
克拉与BC免疫微环境,耐药性和免疫治疗反应有显著的关联.
GSEA揭示了Kla参与激活与BC相关的KEGG通路.

结论:

克拉是乳腺癌中显著的预后生物标志物.
克拉与BC的耐药性和不良免疫反应有关.
克拉代表了乳腺癌治疗的潜在新型治疗标.

关键词:

乳腺癌乳腺癌乳腺癌免疫治疗是一种免疫疗法.克拉克拉克拉克拉克拉乳母乳化乳母乳化乳母乳化预后预后预测预测

更多相关视频

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...